Share
When you hear the words Alzheimer's disease, what do you think of? The truth is, the picture most of us have of the disease is incomplete. Alzheimer's disease doesn't start when someone starts to lose their memory. It actually starts years – sometimes decades – earlier. The Rethinking Alzheimer's Disease Podcast is an engaging, narrative-style podcast miniseries for those curious or motivated to learn about Alzheimer’s disease. Perhaps you have a family member with Alzheimer’s disease, or ca ...
…
continue reading
Manage episode 498931833 series 2769752
Content provided by PCCA - The Leader in Compounding Pharmacy. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by PCCA - The Leader in Compounding Pharmacy or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
In this episode of The Mortar & Pestle: A PCCA Podcast, host Mike de Lisio is joined by PCCA’s VP of R&D, Daniel Banov, and returning guest Richie Ray, owner of Richie Specialty Pharmacy, to explore the innovation and impact of SubMagna—a proprietary sublingual base developed by PCCA. They discuss the technical challenges and scientific breakthroughs involved in formulating SubMagna to effectively deliver high molecular weight peptides like semaglutide via the sublingual route. Daniel details the base’s development process, including surfactant balancing, solubility enhancement, and permeability optimization, while Richie shares clinical insights, patient responses, and the broader market implications. Together, they highlight SubMagna’s potential as a game-changing delivery system for peptides and other challenging APIs, especially in an era of rising demand for non-injectable therapies.
149 episodes
))
